Dual GLP-1/GIP Agonists Show Strong Potential for Cardiovascular Protection
Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention.
Background
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, often exacerbated by metabolic conditions like type 2 diabetes and obesity. Traditional treatments target individual risk factors, but there's a critical need for novel therapeutic strategies that offer comprehensive cardiovascular benefits. This review explores the emerging and multifaceted role of dual GLP-1/GIP receptor agonists in offering superior cardiovascular protection beyond existing therapies.